Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Active organotypic models for nanoparticle toxicological screening

Project description

Novel in vitro biomimetic organs will speed nanoparticle testing

The 'eureka' moment is rarely a moment but rather the result of years of strategic experimentation. ActiTOX is developing in vitro biomimetic systems to speed up nanoparticle-based product testing for safety and toxicity while reducing the use of animal experimentation. The team is exploiting human-induced pluripotent stem cells (iPSCs), former adult somatic cells reprogrammed to their embryonic state. Scientists will reprogramme them to differentiate into cells in tissues of interest. The iPSCs will allow ActiTOX to bypass the ethical issues associated with embryonic stem cells while retaining the ability to create biomimetic organs of choice in culture.

Objective

Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers.
However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animal
testing) and functional (high attrition rate in clinical testing) point of view. ActiTOX reacts to this problem by the development
of a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME
(absorption, distribution, metabolism, excretion) toxicity studies. In order to advance the current state of art the project will
employ biomimetic scaffolds, drug delivery systems, human induced pluripotent stem cells (iPSCs), 3D-microfluidics and
modular bioreactor technology. ActiTOX aims to increase the relevance of in vitro studies and provide a scalable approach
for their use in drug development and toxicological screening.
In order to achieve the project goals, a training network enabling efficient short-term secondments of ER and ESR between
academia and industry will be established. The cooperation between stakeholders helps closing the gap between them and oint innovation to foster the current state of the art. ActiTOX will mediate it via networking, research, training, workshop,
innovation and dissemination actions in form of short-term secondments. The project fulfils the aim of a RISE project and
delivers significant social impact, increases knowledge based economy and creates long lasting cooperation strengthening
the European research area.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-RISE-2018

See all projects funded under this call

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Net EU contribution
€ 188 600,00
Address
HANSASTRASSE 27C
80686 Munchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
€ 188 600,00

Participants (9)